294 related articles for article (PubMed ID: 7931875)
1. Postlicensure effectiveness of the Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer-membrane protein complex conjugate vaccine among Navajo children.
Harrison LH; Tajkowski C; Croll J; Reid R; Hu D; Brenneman G; Weatherholtz RC; Santosham M
J Pediatr; 1994 Oct; 125(4):571-6. PubMed ID: 7931875
[TBL] [Abstract][Full Text] [Related]
2. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data.
Heath PT
Pediatr Infect Dis J; 1998 Sep; 17(9 Suppl):S117-22. PubMed ID: 9781743
[TBL] [Abstract][Full Text] [Related]
3. Antibody response of Navajo children primed with PRP-OMP vaccine to booster doses of PRP-OMP vs. HbOC vaccine.
Reid R; Santosham M; Croll J; Thompson C; Newcomer W; Siber GR
Pediatr Infect Dis J; 1993 Oct; 12(10):812-5. PubMed ID: 8284116
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine in a high risk American Indian population.
Santosham M; Hill J; Wolff M; Reid R; Lukacs L; Ahonkhai V
Pediatr Infect Dis J; 1991 Feb; 10(2):113-7. PubMed ID: 2062601
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
Hu JL; Tao H; Li JX; Dai WM; Song B; Sun JF; Liu P; Tang J; Liu WY; Wang SY; Zhu FC
Hum Vaccin Immunother; 2015; 11(5):1120-8. PubMed ID: 25833163
[TBL] [Abstract][Full Text] [Related]
6. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections.
Lagos R; Horwitz I; Toro J; San Martin O; Abrego P; Bustamante C; Wasserman SS; Levine OS; Levine MM
Pediatr Infect Dis J; 1996 Mar; 15(3):216-22. PubMed ID: 8852909
[TBL] [Abstract][Full Text] [Related]
7. Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants.
Santosham M; Englund JA; McInnes P; Croll J; Thompson CM; Croll L; Glezen WP; Siber GR
Pediatr Infect Dis J; 2001 Oct; 20(10):931-40. PubMed ID: 11642626
[TBL] [Abstract][Full Text] [Related]
8. Prevention of Haemophilus influenzae type b infections in Apache and Navajo children.
Santosham M; Rivin B; Wolff M; Reid R; Newcomer W; Letson GW; Almeido-Hill J; Thompson C; Siber GR
J Infect Dis; 1992 Jun; 165 Suppl 1():S144-51. PubMed ID: 1588150
[TBL] [Abstract][Full Text] [Related]
9. Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants.
Anderson EL; Decker MD; Englund JA; Edwards KM; Anderson P; McInnes P; Belshe RB
JAMA; 1995 Mar; 273(11):849-53. PubMed ID: 7869554
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response.
Dockrell DH; Poland GA; Steckelberg JM; Wollan PC; Strickland SR; Pomeroy C
Vaccine; 1999 Jul; 17(22):2779-85. PubMed ID: 10438047
[TBL] [Abstract][Full Text] [Related]
11. Long-term trends in invasive Haemophilus influenzae type B disease among indigenous Australian children following use of PRP-OMP and PRP-T vaccines.
Menzies RI; Bremner KM; Wang H; Beard FH; McIntyre PB
Pediatr Infect Dis J; 2015 Jun; 34(6):621-6. PubMed ID: 25973940
[TBL] [Abstract][Full Text] [Related]
12. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody.
Lee YC; Kelly DF; Yu LM; Slack MP; Booy R; Heath PT; Siegrist CA; Moxon RE; Pollard AJ
Clin Infect Dis; 2008 Jan; 46(2):186-92. PubMed ID: 18171249
[TBL] [Abstract][Full Text] [Related]
13.
Slack M; Esposito S; Haas H; Mihalyi A; Nissen M; Mukherjee P; Harrington L
Expert Rev Vaccines; 2020 Oct; 19(10):903-917. PubMed ID: 32962476
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.
Lottenbach KR; Granoff DM; Barenkamp SJ; Powers DC; Kennedy D; Irby-Moore S; Homan SM; Mink CM
J Am Geriatr Soc; 2004 Nov; 52(11):1883-7. PubMed ID: 15507066
[TBL] [Abstract][Full Text] [Related]
15. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex.
Santosham M; Wolff M; Reid R; Hohenboken M; Bateman M; Goepp J; Cortese M; Sack D; Hill J; Newcomer W
N Engl J Med; 1991 Jun; 324(25):1767-72. PubMed ID: 1903846
[TBL] [Abstract][Full Text] [Related]
16. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses.
Yogev R; Arditi M; Chadwick EG; Amer MD; Sroka PA
Pediatrics; 1990 Apr; 85(4 Pt 2):690-3. PubMed ID: 2107520
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of Haemophilus b conjugate vaccine (meningococcal protein conjugate) in children with prior invasive Haemophilus influenzae type b disease.
Walter EB; Moggio MV; Drucker RP; Wilfert CM
Pediatr Infect Dis J; 1990 Sep; 9(9):632-5. PubMed ID: 2235187
[TBL] [Abstract][Full Text] [Related]
18. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants.
Granoff DM; Anderson EL; Osterholm MT; Holmes SJ; McHugh JE; Belshe RB; Medley F; Murphy TV
J Pediatr; 1992 Aug; 121(2):187-94. PubMed ID: 1640282
[TBL] [Abstract][Full Text] [Related]
19. The immunogenicity of three Haemophilus influenzae type B conjugate vaccines after a primary vaccination series in Philippine infants.
Capeding MR; Nohynek H; Pascual LG; Kayhty H; Sombrero LT; Eskola J; Ruutu P
Am J Trop Med Hyg; 1996 Nov; 55(5):516-20. PubMed ID: 8940983
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
Dashefsky B; Wald E; Guerra N; Byers C
Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
